Safety, tolerability and clinical effects of BC007 (Rovunaptabin) on fatigue and quality of life in patients with post-COVID syndrome (reCOVer): a prospective, exploratory, randomised, placebo-controlled, double-blind, crossover phase IIa clinical trial

Bettina Hohberger, Marion Ganslmayer, Thomas Harrer, Friedrich Kruse, Stefanie Maas, Tobias Borst, Ralph Heimke-Brinck, Andreas Stog, Thomas Knauer, Eva Rühl, Victoria Zeisberg, Adam Skornia, Alexander Bartsch, Armin Ströbel, Monika Wytopil, Carolin Merkel, Sophia Hofmann, Katja G. Schmidt, Petra Lakatos, Julia Schottenhamml, Martin Herrmann, Christian Mardin, Jürgen Rech
doi: https://doi.org/10.1101/2024.12.13.24318856

Data Availability

All data produced in the present study are available upon reasonable request to the authors.

Back to top
Posted December 14, 2024.
Download PDF

Supplementary Material

Data/Code
Email
Safety, tolerability and clinical effects of BC007 (Rovunaptabin) on fatigue and quality of life in patients with post-COVID syndrome (reCOVer): a prospective, exploratory, randomised, placebo-controlled, double-blind, crossover phase IIa clinical trial
Bettina Hohberger, Marion Ganslmayer, Thomas Harrer, Friedrich Kruse, Stefanie Maas, Tobias Borst, Ralph Heimke-Brinck, Andreas Stog, Thomas Knauer, Eva Rühl, Victoria Zeisberg, Adam Skornia, Alexander Bartsch, Armin Ströbel, Monika Wytopil, Carolin Merkel, Sophia Hofmann, Katja G. Schmidt, Petra Lakatos, Julia Schottenhamml, Martin Herrmann, Christian Mardin, Jürgen Rech
medRxiv 2024.12.13.24318856; doi: https://doi.org/10.1101/2024.12.13.24318856
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area